Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL

Charles Herbaux • 10 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Atezolizumab Obinutuzumab Venetoclax
LYSA

Charles Herbaux MD, MSc, CHU de Lille, Lille University Hospital, Lille, France, discusses the results from the LYSA study (NCT03276468), a Phase II trial evaluating the efficacy and safety of combining atezolizumab, obinutuzumab and venetoclax in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Charles Herbaux

1:46
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux • 25 May 2021
1:26
Ruxolitinib plus venetoclax for T-PLL: rationale and findings
Charles Herbaux • 25 May 2021
2:50
Nivolumab and allogeneic transplantation in R/R classical Hodgkin lymphoma
Charles Herbaux • 10 Jun 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals